{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:00:04Z","timestamp":1794549604133,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40265-023-01954-w","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T05:02:12Z","timestamp":1699074132000},"page":"1621-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Elranatamab: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"issue":"10396","key":"1954_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142\u201358.","journal-title":"Lancet"},{"issue":"3","key":"1954_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen Y, Park J, et al. Design and production of bispecific antibodies. Antibodies (Basel). 2019;8(3):43.","journal-title":"Antibodies (Basel)."},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.","journal-title":"Front Immunol"},{"key":"1954_CR4","unstructured":"US FDA. BLA accelerated approval (elranatamab-bcmm). 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/761345Orig1s000ltr.pdf. Accessed 28 Aug 2023."},{"key":"1954_CR5","unstructured":"Pfizer Inc. ELREXFIOTM (elranatamab-bcmm): US prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669. Accessed 28 Aug 2023."},{"key":"1954_CR6","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Elrexfio (elranatamab). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-elrexfio_en.pdf. Accessed 18 Oct 2023."},{"key":"1954_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"key":"1954_CR8","doi-asserted-by":"crossref","unstructured":"Dalovisio A, Bahlis N, Raje N, et al. Updated results from the ongoing phase 1 study of elranatamab, a BCMA targered T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma [abstract no. P897]. HemaSphere. 2022;6(S3):1509\u201310.","DOI":"10.1097\/01.HS9.0000846460.44039.3d"},{"issue":"Suppl 1","key":"1954_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2022-166494","volume":"140","author":"N Raje","year":"2022","unstructured":"Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bspecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2022;140(Suppl 1):388\u201390.","journal-title":"Blood"},{"key":"1954_CR10","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Quach H, Weisel K, et al. Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A [abstract no. P906]. HemaSphere. 2023;7(S3):1709\u201310.","DOI":"10.1097\/01.HS9.0000970528.04188.9f"},{"issue":"Supplement 1","key":"1954_CR11","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1182\/blood-2022-169971","volume":"140","author":"M Elmeliegy","year":"2022","unstructured":"Elmeliegy M, Viqueira A, Vandendries E, et al. Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma [abstract]. Blood. 2022;140(Supplement 1):7174\u20135.","journal-title":"Blood"},{"key":"1954_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1954_CR13","doi-asserted-by":"crossref","unstructured":"Manier S, Lesokhin A, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies [abstract no. P870 plus poster]. HemaSphere. 2023;7(S3):1633\u201334.","DOI":"10.1097\/01.HS9.0000970384.26808.c7"},{"key":"1954_CR14","doi-asserted-by":"crossref","unstructured":"Leleu X, Iida S, Landgren CO, et al. Elranatamab monotherapy or in combination with daratumumab vs daratumumab + pomalidomide + dexamethasone for patients with relapsed\/refractory multiple myeloma: phase 3 MagnetisMM-5 Study, Part 2 [abstract no. P930]. HemaSphere. 2023;7(S3):1758.","DOI":"10.1097\/01.HS9.0000970624.05231.6a"},{"key":"1954_CR15","doi-asserted-by":"crossref","unstructured":"Manteca MVM, Grosicki S, Kim K. Magnetismm-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly dagnosed multiple myeloma [abstract no. PB2131]. HemaSphere. 2023;7(S3):4084.","DOI":"10.1097\/01.HS9.0000975288.42582.76"},{"key":"1954_CR16","doi-asserted-by":"crossref","unstructured":"Manteca MVM, Grosicki S, Kim K. MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma [abstract no. TPS8066]. J Clin Oncol. 2023;41(16 Suppl).","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"issue":"Suppl 1","key":"1954_CR17","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1182\/blood-2022-166854","volume":"140","author":"O Landgren","year":"2022","unstructured":"Landgren O, Kazandjian D, O\u2019Connell A, et al. Magnetismm-4: an open label, phase 1b\/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma. Blood. 2022;140(Suppl 1):10172\u20133.","journal-title":"Blood"},{"key":"1954_CR18","doi-asserted-by":"crossref","unstructured":"Fonseca R, Kuroda J, Ishida T, et al. MagnetisMM-9: an open-label, multicenter, non-randomized phase 1\/2 study of elranatamab in patients with relapsed\/refractory multiple myeloma [abstract no. TPS8068]. J Clin Oncol. 2022;40(16 Suppl).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8068"},{"key":"1954_CR19","doi-asserted-by":"crossref","unstructured":"Fonseca R, Kuroda J, Ishida T, et al. MafnetisMM-9: an open-label, multicenter, non-randomized phase 1\/2 study of elranatamab in patients with relapsed\/refractory multiple myeloma [abstract no. PB2032]. HemaSphere. 2022;6(S3):3518.","DOI":"10.1097\/01.HS9.0000850960.38950.59"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01954-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T05:13:59Z","timestamp":1701494039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01954-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01954-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"4 November 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}